Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment

The current standard of care for colorectal cancer (CRC) is a combination of chemotherapeutics, often supplemented with targeted biological drugs. An urgent need exists for improved drug efficacy and minimized side effects, especially at late‐stage disease. We employed the phenotypically driven ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoetemelk, Marloes, Ramzy, George M., Rausch, Magdalena, Koessler, Thibaud, van Beijnum, Judy R., Weiss, Andrea, Mieville, Valentin, Piersma, Sander R., de Haas, Richard R., Delucinge‐Vivier, Céline, Andres, Axel, Toso, Christian, Henneman, Alexander A., Ragusa, Simone, Petrova, Tatiana V., Docquier, Mylène, McKee, Thomas A., Jimenez, Connie R., Daali, Youssef, Griffioen, Arjan W., Rubbia‐Brandt, Laura, Dietrich, Pierre‐Yves, Nowak‐Sliwinska, Patrycja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607171/
https://www.ncbi.nlm.nih.gov/pubmed/33021054
http://dx.doi.org/10.1002/1878-0261.12797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607171/
https://www.ncbi.nlm.nih.gov/pubmed/33021054
http://dx.doi.org/10.1002/1878-0261.12797

Ejemplares similares